Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,920,000 shares, a decrease of 11.1% from the August 15th total of 4,410,000 shares. Based on an average daily trading volume, of 830,700 shares, the days-to-cover ratio is currently 4.7 days.
Arbutus Biopharma Price Performance
Shares of Arbutus Biopharma stock opened at $2.22 on Monday. Arbutus Biopharma has a 1 year low of $1.93 and a 1 year high of $6.50. The business has a 50-day moving average of $2.38 and a two-hundred day moving average of $2.57. The company has a market capitalization of $332.89 million, a P/E ratio of -3.70 and a beta of 2.24.
Arbutus Biopharma (NASDAQ:ABUS – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03. Arbutus Biopharma had a negative return on equity of 61.57% and a negative net margin of 211.09%. During the same period in the prior year, the company earned ($0.23) earnings per share. On average, equities analysts anticipate that Arbutus Biopharma will post -0.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, JMP Securities cut their target price on Arbutus Biopharma from $10.00 to $9.00 and set a “market outperform” rating on the stock in a research note on Tuesday, June 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.13.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication.
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.